Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 6/2014

01-11-2014 | Original Article

Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study

Authors: L. J. Anderson, W. Henley, K. M. Wyatt, V. Nikolaou, D. A. Hughes, S. Waldek, S. Logan

Published in: Journal of Inherited Metabolic Disease | Issue 6/2014

Login to get access

Abstract

Objectives

To determine the effectiveness of enzyme replacement therapies (ERT) for adults with Gaucher disease (GD).

Design

A longitudinal, multi-centre cohort study, including prospective and retrospective clinical data. Age- and gender-adjusted treatment effects were estimated using generalised linear mixed models. Treated patients contributed data before and during treatment. Untreated patients contributed natural history data.

Participants

Consenting adults (N = 150, aged 16 to 83 years) with a diagnosis of GD who attended a specialist treatment centre in England. At recruitment, 131 patients were receiving ERT (mean treatment duration, 10.8 years; range 0–18 years).

Outcome measures

Clinical outcomes chosen to reflect disease progression, included platelet count; haemoglobin; absence/presence of bone pain; spleen and liver volumes and AST levels.

Results

One hundred and fifty adults were recruited. Duration of ERT was associated with statistically significant improvements in platelet count (p < 0.001), haemoglobin (p < 0.001), liver and spleen volumes (p < 0.001) and AST levels (p = 0.02).

Conclusions

These data provide further evidence of the long-term effectiveness of ERT in adults with GD.
Literature
go back to reference Andersson H, Kaplan P, Kacena K, Yee J (2008) Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 122(6):1182–1190PubMedCrossRef Andersson H, Kaplan P, Kacena K, Yee J (2008) Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 122(6):1182–1190PubMedCrossRef
go back to reference Biegstraaten M, Mengel E, Marodi L et al (2010) Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain 133(10):2909–2919PubMedCrossRef Biegstraaten M, Mengel E, Marodi L et al (2010) Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain 133(10):2909–2919PubMedCrossRef
go back to reference Brady RO, Kanfer J, Shapiro D (1965) The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue. J Biol Chem 240:39–43PubMed Brady RO, Kanfer J, Shapiro D (1965) The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue. J Biol Chem 240:39–43PubMed
go back to reference Charrow J, Dulisse B, Grabowski GA, Weinreb NJ (2007) The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 71(3):205–211PubMedCrossRef Charrow J, Dulisse B, Grabowski GA, Weinreb NJ (2007) The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 71(3):205–211PubMedCrossRef
go back to reference Connock M, Burls A, Frew E et al (2006) The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher’s disease: a systematic review. Health Technol Assess 10(24):iii–iv, ix-136CrossRef Connock M, Burls A, Frew E et al (2006) The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher’s disease: a systematic review. Health Technol Assess 10(24):iii–iv, ix-136CrossRef
go back to reference Cox T, Lachmann R, Hollak C et al (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355(9214):1481–1485PubMedCrossRef Cox T, Lachmann R, Hollak C et al (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355(9214):1481–1485PubMedCrossRef
go back to reference Deegan PB, Pavlova E, Tindall J et al (2011) Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 90(1):52–60CrossRef Deegan PB, Pavlova E, Tindall J et al (2011) Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 90(1):52–60CrossRef
go back to reference El-Beshlawy A, Ragab L, Youssry I et al (2006) Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis 29(1):92–98PubMedCrossRef El-Beshlawy A, Ragab L, Youssry I et al (2006) Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis 29(1):92–98PubMedCrossRef
go back to reference Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A (2011a) Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol Dis 46(1):119–123PubMedCrossRef Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A (2011a) Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol Dis 46(1):119–123PubMedCrossRef
go back to reference Elstein D, Foldes AJ, Zahrieh D et al (2011b) Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. Blood Cells Mol Dis 47(1):56–61PubMedCrossRef Elstein D, Foldes AJ, Zahrieh D et al (2011b) Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. Blood Cells Mol Dis 47(1):56–61PubMedCrossRef
go back to reference European Medicines Agency (2009) Questions and answers on the shortages of Cerezyme and Fabrazyme. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500018393.pdf European Medicines Agency (2009) Questions and answers on the shortages of Cerezyme and Fabrazyme. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​Medicine_​QA/​2009/​12/​WC500018393.​pdf
go back to reference Grabowski GA, Barton NW, Pastores G et al (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122(1):33–39PubMedCrossRef Grabowski GA, Barton NW, Pastores G et al (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122(1):33–39PubMedCrossRef
go back to reference Grabowski GA, Petsko GA, Kolody EH (2010) Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS (eds) The online metabolic and molecular bases of inherited disease. McGraw-Hill, New York, p 146 Grabowski GA, Petsko GA, Kolody EH (2010) Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS (eds) The online metabolic and molecular bases of inherited disease. McGraw-Hill, New York, p 146
go back to reference Henley W, Anderson LJ, Wyatt KM, Nikolaou V, Anderson R, Logan S (2014) The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with Lysosomal Storage Disorders. JIMD Rep Henley W, Anderson LJ, Wyatt KM, Nikolaou V, Anderson R, Logan S (2014) The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with Lysosomal Storage Disorders. JIMD Rep
go back to reference Hsu CC, Chien YH, Lai MY, Hwu WL (2002) Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease. J Formos Med Assoc 101(9):627–631PubMed Hsu CC, Chien YH, Lai MY, Hwu WL (2002) Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease. J Formos Med Assoc 101(9):627–631PubMed
go back to reference Pastores GM, Patel MJ, Firooznia H (2000) Bone and joint complications related to Gaucher disease. Curr Rheumatol Rep 2(2):175–180PubMedCrossRef Pastores GM, Patel MJ, Firooznia H (2000) Bone and joint complications related to Gaucher disease. Curr Rheumatol Rep 2(2):175–180PubMedCrossRef
go back to reference Rodrigue SW, Rosenthal DI, Barton NW, Zurakowski D, Mankin HJ (1999) Risk factors for osteonecrosis in patients with type 1 Gaucher’s disease. Clin Orthop Relat Res 362:201–207PubMedCrossRef Rodrigue SW, Rosenthal DI, Barton NW, Zurakowski D, Mankin HJ (1999) Risk factors for osteonecrosis in patients with type 1 Gaucher’s disease. Clin Orthop Relat Res 362:201–207PubMedCrossRef
go back to reference Rosenthal DI, Scott JA, Barranger J et al (1986) Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg Am 68(6):802–808PubMed Rosenthal DI, Scott JA, Barranger J et al (1986) Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg Am 68(6):802–808PubMed
go back to reference Schiffmann R, Mankin H, Dambrosia JM et al (2002) Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 28(2):288–296PubMedCrossRef Schiffmann R, Mankin H, Dambrosia JM et al (2002) Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 28(2):288–296PubMedCrossRef
go back to reference Sims KB, Pastores GM, Weinreb NJ et al (2008) Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 73(5):430–440PubMedCrossRefPubMedCentral Sims KB, Pastores GM, Weinreb NJ et al (2008) Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet 73(5):430–440PubMedCrossRefPubMedCentral
go back to reference Tayebi N, Callahan M, Madike V et al (2001) Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73(4):313–321PubMedCrossRef Tayebi N, Callahan M, Madike V et al (2001) Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73(4):313–321PubMedCrossRef
go back to reference Weinreb NJ, Charrow J, Andersson HC et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113(2):112–119PubMedCrossRef Weinreb NJ, Charrow J, Andersson HC et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113(2):112–119PubMedCrossRef
go back to reference Weinreb N, Barranger J, Packman S et al (2007) Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 71(6):576–588PubMedCrossRef Weinreb N, Barranger J, Packman S et al (2007) Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 71(6):576–588PubMedCrossRef
go back to reference Wenstrup RJ, Kacena KA, Kaplan P et al (2007) Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 22(1):119–126PubMedCrossRef Wenstrup RJ, Kacena KA, Kaplan P et al (2007) Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 22(1):119–126PubMedCrossRef
go back to reference Wyatt K, Henley W, Anderson L et al (2012) The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess 16(39):1–543PubMedCrossRef Wyatt K, Henley W, Anderson L et al (2012) The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess 16(39):1–543PubMedCrossRef
go back to reference Zimran A, Morris E, Mengel E et al (2009) The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 43(3):264–288PubMedCrossRef Zimran A, Morris E, Mengel E et al (2009) The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 43(3):264–288PubMedCrossRef
go back to reference Zimran A, Altarescu G, Philips M et al (2010) Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 115(23):4651–4656PubMedCrossRef Zimran A, Altarescu G, Philips M et al (2010) Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 115(23):4651–4656PubMedCrossRef
Metadata
Title
Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study
Authors
L. J. Anderson
W. Henley
K. M. Wyatt
V. Nikolaou
D. A. Hughes
S. Waldek
S. Logan
Publication date
01-11-2014
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 6/2014
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-014-9680-0

Other articles of this Issue 6/2014

Journal of Inherited Metabolic Disease 6/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.